The Schall Law Firm is reminding investors of a class action lawsuit against Ardent Health, Inc. (NYSE: ARDT) for securities fraud. The company allegedly made false and misleading statements regarding accounts receivable collection practices and failed to maintain adequate professional malpractice liability insurance. Investors who purchased securities between July 18, 2024 and November 12, 2025 are encouraged to join the lawsuit before the March 9, 2026 deadline.

A class action lawsuit has been filed against Ardent Health, Inc. alleging that the company made materially false and misleading statements regarding its Q3 2025 revenue and 2025 EBITDA guidance. The complaint claims revenue was overstated due to inadequate accounts receivable assessments following a new accounting system implementation, and EBITDA guidance was overstated by approximately $57.5 million (9.6%) due to industry-wide cost pressures and payer denials. Investors who purchased Ardent securities between July 18, 2024 and November 12, 2025 are encouraged to join the lawsuit.

Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against Ardent Health, Inc., alleging the company misrepresented its receivables and collection practices. The lawsuit follows a 33% stock decline on November 13, 2025, after Ardent Health disclosed a $43 million revenue decrease and $54 million increase in professional liability reserves. Investors have until March 9, 2026, to request lead plaintiff status.

Holzer & Holzer, LLC announces March 9, 2026 deadline for investors to seek lead plaintiff status in shareholder class action lawsuits against Ardent Health, Inc. and Varonis Systems, Inc. Ardent Health faces allegations of false statements regarding accounts receivable collectability (July 2024-November 2025), while Varonis faces allegations regarding misstatements about customer conversion ability and ARR growth potential (February-October 2025).

Ardent Health faces a securities class action lawsuit for failing to disclose material information. On November 12, 2025, the company revealed a $43 million revenue decrease, cut 2025 EBITDA guidance by $57.5 million, and increased professional liability reserves by $54 million. The stock fell 34% from $14.05 to $9.30 per share on the news. Investors with losses exceeding $100,000 have until March 9, 2026 to file lead plaintiff applications.

A class action lawsuit has been filed against Ardent Health, Inc. alleging that the company made materially false and misleading statements regarding its Q3 2025 revenue and 2025 EBITDA guidance. The complaint claims revenue was overstated due to inadequate accounts receivable assessments following a new accounting system implementation, and EBITDA guidance was overstated by approximately $57.5 million due to industry-wide cost pressures and payer denials. Investors who purchased Ardent securities between July 18, 2024 and November 12, 2025 are encouraged to join the lawsuit.

A class action lawsuit has been filed against Ardent Health, Inc. for allegedly reporting inflated accounts receivable and delaying loss recognition during the period from July 18, 2024 to November 12, 2025. The company revealed a $43 million revenue decrease in Q3 2025 after transitioning to a new accounting system, causing the stock to plummet 34% from $14.05 to $9.30 per share. Investors have until March 9, 2026 to apply as lead plaintiff.

Pomerantz LLP has filed a class action lawsuit against Ardent Health, Inc. alleging securities fraud and unlawful business practices. The lawsuit stems from Ardent's November 2025 disclosure of a $43 million revenue decrease due to a new accounting system revealing higher accounts receivable reserves, combined with a $57.5 million EBITDA guidance cut and a $54 million increase in professional liability reserves. The stock fell 33.81% following the announcement. The deadline to join the class action is March 9, 2026.

Pomerantz Law Firm has filed class action lawsuits against Bath & Body Works, Ardent Health, and Varonis Systems for alleged securities fraud. Bath & Body Works faced significant stock declines following disappointing Q2 and Q3 2025 earnings reports, with revenue missing guidance and full-year earnings guidance slashed substantially. Investors with losses are urged to contact the firm by March 16, 2026, to potentially serve as lead plaintiff.

Ardent Health faces a securities class action lawsuit alleging the company used a rigid 180-day cliff method to reserve for uncollectible accounts, contradicting prior claims of detailed historical reviews. The company also recorded a $54 million spike in professional liability reserves and slashed revenue by $42.6 million in November 2025, triggering a 33% stock collapse. The lead plaintiff deadline is March 9, 2026.

Rosen Law Firm has filed class action lawsuits against Enphase Energy, Inovio Pharmaceuticals, and Ardent Health for alleged securities fraud. Enphase is accused of overstating its channel inventory management capabilities and ability to mitigate effects from the termination of the Residential Clean Energy Credit, resulting in materially false financial statements. Investors who purchased securities during specified class periods may be eligible for compensation.

Rosen Law Firm has filed securities class action lawsuits against multiple companies. Ardent Health is accused of misrepresenting accounts receivable accounting practices and maintaining insufficient professional malpractice insurance. Smart Digital Group and Oracle Corporation also face similar legal action. Investors with losses exceeding $100,000 are encouraged to join the class actions before the March 9, 2026 deadline.